Jazz Pharmaceuticals (JAZZ) Change in Receivables (2010 - 2026)

Jazz Pharmaceuticals' Change in Receivables history runs 17 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 109.85% year-over-year to $6.5 million in Q1 2026; TTM through Mar 2026 was $178.8 million, a 435.24% increase from a year earlier, with the FY2025 full-year figure at $106.3 million, up 403.33% from the prior year.
• Change in Receivables retreated to $6.5 million in Q1 2026 per JAZZ's latest filing, from $65.8 million in the prior quarter.
• Across five years, Change in Receivables topped out at $75.5 million in Q4 2023 and bottomed at -$66.0 million in Q1 2025.
• The 5-year median for Change in Receivables is $9.7 million (2022), against an average of $16.2 million.
• Biggest YoY gain for Change in Receivables was 7717.25% in 2025; the steepest drop was 881.71% in 2025.
• Year by year, Change in Receivables stood at $46.3 million in 2022, then soared by 63.11% to $75.5 million in 2023, then slumped by 101.14% to -$864000.0 in 2024, then surged by 7717.25% to $65.8 million in 2025, then sank by 90.12% to $6.5 million in 2026.
• Per Business Quant, the three latest JAZZ Change in Receivables figures stand at $6.5 million (Q1 2026), $65.8 million (Q4 2025), and $51.0 million (Q3 2025).